|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
96,118,000 |
Market
Cap: |
1.54(B) |
Last
Volume: |
115,349 |
Avg
Vol: |
115,034 |
52
Week Range: |
$9.64 - $17.22 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Avadel Pharmaceuticals is a biopharmaceutical company. Co.'s primary product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. Co.'s commercial products are: Akovaz, which is indicated for the treatment of hypotension occurring in the setting of anesthesia; Bloxiverz, which is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep®, which is for the treatment of hypotension occuring in the setting of anesthesia; and Nouress, which is a sterile injectable product for use in the hospital setting.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
2,000 |
28,000 |
70,500 |
Total Buy Value |
$0 |
$29,000 |
$377,497 |
$804,952 |
Total People Bought |
0 |
1 |
3 |
5 |
Total Buy Transactions |
0 |
1 |
4 |
9 |
Total Shares Sold |
0 |
75,000 |
103,975 |
103,975 |
Total Sell Value |
$0 |
$1,089,750 |
$1,522,364 |
$1,522,364 |
Total People Sold |
0 |
1 |
1 |
1 |
Total Sell Transactions |
0 |
1 |
2 |
2 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Elrod Marcus W |
See Remarks |
|
2016-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
58,000 |
|
- |
|
Hatten Sandra L |
See Remarks |
|
2016-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
58,000 |
|
- |
|
Kanan Michael F |
See Remarks |
|
2016-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
58,000 |
|
- |
|
Monteith David |
See Remarks |
|
2016-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
58,000 |
|
- |
|
Sullivan Stephen G. |
See Remarks |
|
2016-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
58,000 |
|
- |
|
Thompson Phillandas T. |
See Remarks |
|
2016-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
58,000 |
|
- |
|
Stapleton Craig R |
Director |
|
2016-11-29 |
4 |
B |
$10.85 |
$108,500 |
I/I |
10,000 |
40,000 |
2.1 |
- |
|
Stapleton Craig R |
Director |
|
2016-11-28 |
4 |
B |
$10.74 |
$107,370 |
I/I |
10,000 |
30,000 |
2.1 |
- |
|
Anderson Michael S |
Chief Executive Officer |
|
2016-11-21 |
4 |
B |
$10.64 |
$21,274 |
D/D |
2,000 |
193,250 |
2.81 |
- |
|
Fildes Francis |
Director |
|
2016-09-22 |
4 |
S |
$13.45 |
$201,750 |
D/D |
(15,000) |
15,000 |
|
- |
|
Anderson Michael S |
Chief Executive Officer |
|
2016-09-02 |
4 |
B |
$14.12 |
$28,240 |
D/D |
2,000 |
191,250 |
2.81 |
- |
|
Stapleton Craig R |
Director |
|
2016-09-01 |
4 |
B |
$13.52 |
$135,190 |
D/D |
10,000 |
519,678 |
2.39 |
- |
|
Stapleton Craig R |
Director |
|
2016-08-26 |
4 |
B |
$13.67 |
$275,140 |
I/I |
20,000 |
20,000 |
2.1 |
- |
|
Anderson Michael S |
Chief Executive Officer |
|
2016-08-22 |
4 |
B |
$14.30 |
$71,479 |
D/D |
5,000 |
189,250 |
2.81 |
- |
|
Anderson Michael S |
Chief Executive Officer |
|
2016-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
184,250 |
|
- |
|
Macke Scott A. |
See Remarks |
|
2016-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
42,000 |
|
- |
|
Davis Gregory J. |
See Remarks |
|
2016-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
Thompson Phillandas T. |
See Remarks |
|
2016-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
40,000 |
|
- |
|
Monteith David |
See Remarks |
|
2016-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
17,500 |
|
- |
|
Hatten Sandra L |
See Remarks |
|
2016-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
23,000 |
|
- |
|
Stapleton Craig R |
Director |
|
2016-05-16 |
4 |
B |
$9.25 |
$22,339 |
D/D |
2,415 |
509,678 |
2.39 |
- |
|
Stapleton Craig R |
Director |
|
2016-05-13 |
4 |
B |
$9.21 |
$228,553 |
D/D |
24,813 |
507,263 |
2.39 |
- |
|
Anderson Michael S |
Chief Executive Officer |
|
2016-05-12 |
4 |
B |
$8.84 |
$44,200 |
D/D |
5,000 |
134,250 |
2.81 |
- |
|
Thompson Phillandas T. |
See Remarks |
|
2016-03-22 |
4 |
B |
$11.10 |
$111,030 |
D/D |
10,000 |
20,000 |
2.74 |
- |
|
Anderson Michael S |
Chief Executive Officer |
|
2016-03-18 |
4 |
B |
$11.04 |
$55,220 |
D/D |
5,000 |
129,250 |
2.81 |
- |
|
186 Records found
|
|
Page 7 of 8 |
|
|